Earlier this year, Denali Therapeutics completed a US$200,000,000 secondary offering of common shares and pre-funded warrants while engaging with the FDA on a potential priority review voucher linked ...
In recent days, Monster Beverage has attracted fresh attention as analyst and AI-driven research pointed to strong near-term sentiment supported by solid sales performance, favorable pricing trends, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback